Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Risk factors for nonadherence to warfarin: results from the IN-RANGE study.

Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Laskin MS, Kimmel SE.

Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):853-60. doi: 10.1002/pds.1556.

2.

Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.

Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Laskin MS, Kimmel SE.

Chest. 2010 Apr;137(4):883-9. doi: 10.1378/chest.09-0039. Epub 2009 Nov 10.

3.

Nonadherence with INR monitoring and anticoagulant complications.

Witt DM, Delate T, Clark NP, Garcia DA, Hylek EM, Ageno W, Dentali F, Crowther MA.

Thromb Res. 2013 Aug;132(2):e124-30. doi: 10.1016/j.thromres.2013.06.006. Epub 2013 Jun 22.

PMID:
23800635
4.

The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.

Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Gross R.

Arch Intern Med. 2007 Feb 12;167(3):229-35.

PMID:
17296877
5.

Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study.

Parker CS, Chen Z, Price M, Gross R, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Kimmel SE.

J Gen Intern Med. 2007 Sep;22(9):1254-9. Epub 2007 Jun 22.

6.

Effect of warfarin nonadherence on control of the International Normalized Ratio.

Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF.

Am J Health Syst Pharm. 2004 Jun 15;61(12):1258-64.

PMID:
15259756
7.

Health literacy and anticoagulation-related outcomes among patients taking warfarin.

Fang MC, Machtinger EL, Wang F, Schillinger D.

J Gen Intern Med. 2006 Aug;21(8):841-6.

8.

Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population.

Nochowitz B, Shapiro NL, Nutescu EA, Cavallari LH.

Ann Pharmacother. 2009 Jul;43(7):1165-72. doi: 10.1345/aph.1L707. Epub 2009 Jun 23.

PMID:
19549747
9.

Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics.

Cruess DG, Localio AR, Platt AB, Brensinger CM, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Kimmel SE.

Int J Behav Med. 2010 Mar;17(1):33-42. doi: 10.1007/s12529-009-9052-6.

10.

Practical management approaches to anticoagulation non-compliance, health literacy, and limited English proficiency in the outpatient clinic setting.

Seliverstov I.

J Thromb Thrombolysis. 2011 Apr;31(3):321-5. doi: 10.1007/s11239-011-0560-2. Review.

PMID:
21337118
11.

Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.

Anthony CJ, Karim S, Ackroyd-Stolarz S, Fry A, Murphy NG, Christie R, Zed PJ.

Ann Pharmacother. 2011 Jul;45(7-8):881-7. doi: 10.1345/aph.1P670. Epub 2011 Jul 12.

PMID:
21750309
12.

Warfarin discontinuation after starting warfarin for atrial fibrillation.

Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE.

Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):624-31. doi: 10.1161/CIRCOUTCOMES.110.937680. Epub 2010 Oct 19.

13.

Use of direct observed therapy to confirm compliance in a warfarin clinic.

Deen R.

J Patient Saf. 2011 Dec;7(4):232-3. doi: 10.1097/PTS.0b013e3182382efc.

PMID:
22064623
14.

Factors affecting medication adherence and anticoagulation control in Korean patients taking warfarin.

Kim JH, Kim GS, Kim EJ, Park S, Chung N, Chu SH.

J Cardiovasc Nurs. 2011 Nov-Dec;26(6):466-74. doi: 10.1097/JCN.0b013e31820914e7.

PMID:
21912274
15.

Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.

Ripley TL, Harrison D, Germany RE, Adamson PB.

Clin Ther. 2010 Mar;32(3):506-14. doi: 10.1016/j.clinthera.2010.03.001.

PMID:
20399987
16.

Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.

Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA; Warfarin-Associated Research Projects and Other Endeavors Consortium.

Pharmacotherapy. 2008 Aug;28(8):960-7. doi: 10.1592/phco.28.8.960.

PMID:
18657012
17.
18.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
19.

The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.

Deerhake JP, Merz JC, Cooper JV, Eagle KA, Fay WP.

J Thromb Thrombolysis. 2007 Apr;23(2):107-13.

PMID:
17221327
20.
Items per page

Supplemental Content

Write to the Help Desk